Multiple large population studies conducted since the pandemic began have found that adults who had COVID-19 face a measurably higher risk of being diagnosed with asthma afterward, even if they had no history of the disease. The size of that increased risk varies across studies, from roughly 16 percent higher in one nationwide Korean cohort to more than double in a multinational analysis spanning three countries. The pattern is consistent enough to be taken seriously, but the story gets more complicated when you look at who is affected, how the lungs change, and whether the breathing problems that follow COVID are truly asthma or something else entirely.
What the Adult Population Data Show
Three of the strongest pieces of evidence come from large retrospective cohort studies that tracked thousands of people who had COVID-19 and compared them against matched groups of people who did not. A nationwide Korean study using national insurance data found that the COVID-19 group had an adjusted hazard ratio of 1.16 for new-onset asthma compared to uninfected controls, and that risk climbed further among those who had severe infections.1PubMed Central. New-onset asthma following COVID-19 in adults A separate multicenter retrospective study pegged the risk slightly higher, with an adjusted hazard ratio of 1.27 for new-onset asthma in the COVID-19 group. That study tracked over 4,200 new asthma diagnoses in the COVID-19 group versus about 3,350 in the control group during follow-up.2PubMed Central. New-onset obstructive airway disease following COVID-19: a multicenter retrospective cohort study
The highest estimate came from a multinational analysis using cohorts from South Korea, Japan, and the United Kingdom, which found a hazard ratio of 2.25 for incident asthma after SARS-CoV-2 infection. That same study found elevated risks for allergic rhinitis and overall allergic diseases, suggesting COVID may push the immune system toward allergic-type responses more broadly. People with moderate-to-severe COVID had a substantially higher risk than those with mild illness.3Nature Communications. Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK
The spread from a 16 percent increase to a twofold-plus increase is wide, and it reflects differences in how the studies defined COVID-19, measured asthma, selected comparison groups, and adjusted for confounders. But every large adult study points in the same direction: COVID raises the odds of a new asthma diagnosis.
Children Tell a Different Story
If you are a parent who worried your child might develop asthma after catching COVID, the pediatric data offer some reassurance. A study published in Pediatrics followed children after SARS-CoV-2 PCR testing and found no significant association between a positive test and a new asthma diagnosis over 18 months. The hazard ratio was 0.96, which is statistically indistinguishable from no effect at all.4PubMed Central. COVID-19 and Asthma Onset in Children
Why the difference between adults and children? Researchers do not have a definitive answer. Children’s airways are still developing and may respond differently to viral insult. It is also possible that adults accumulate more of the underlying susceptibility factors, like airway inflammation from years of environmental exposure, that COVID then tips over the edge. A separate retrospective study comparing respiratory sequelae after RSV, COVID, and influenza in hospitalized children found that RSV posed a substantially larger risk of long-term respiratory diagnoses than either COVID or influenza.5PubMed. Long-term sequelae post-hospitalization for respiratory syncytial virus vs. Omicron SARS-CoV-2 or influenza in adults and children: a retrospective cohort study So for children, COVID may simply not be the strongest respiratory threat in the viral landscape.
What COVID Does to the Airways
To understand why COVID might trigger asthma in adults, it helps to look at what happens to the lungs after infection. Autopsies and lung biopsies from patients with long-term COVID have revealed a striking pattern of airway remodeling. Researchers found that the SARS-CoV-2 receptor, ACE-2, was expressed on both airway and deep lung epithelial cells, meaning the virus could infect cells throughout the respiratory tract. In patients who died from COVID, the lung tissue showed widespread alveolar damage alongside a distinct pattern of airway epithelial cell overgrowth. This hyperplasia extended into the small distal airspaces, which were filled with cellular debris and mucus, with immune cells congregating in nearby blood vessels and tissue.6PubMed Central. Lung Remodeling Regions in Long-Term Coronavirus Disease 2019 Feature Basal Epithelial Cell Reprogramming
That kind of structural change, where the airway lining thickens and mucus production increases, maps closely onto what happens in asthma. The overgrowth of epithelial cells and the immune activation in the surrounding tissue could leave the airways chronically inflamed and hyperreactive to triggers. Meanwhile, a separate line of research has explored whether COVID triggers autoantibodies that linger after the acute infection clears. A systematic review found that autoantibodies were present in the blood of many COVID survivors, and some of these, particularly anti-U1-snRNP and anti-SS-B/La, were associated with persistent symptoms like fatigue and shortness of breath.7PubMed Central. Autoantibodies in COVID-19 survivors with post-COVID symptoms: a systematic review Whether these autoantibodies directly contribute to airway inflammation or are just markers of immune dysregulation remains an open question.
An Unexpected Twist in Severity
You might assume that the sickest COVID patients would be the most likely to develop asthma afterward. Some studies support this: the Korean cohort and the multinational analysis both found that severe or moderate-to-severe COVID carried a higher risk of subsequent asthma than mild illness.3Nature Communications. Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK But the multicenter retrospective study found something puzzling: the increased asthma risk was driven by people who had COVID but were never hospitalized. Among hospitalized and critically ill patients, the study found no statistically significant increase in new-onset asthma compared to controls.2PubMed Central. New-onset obstructive airway disease following COVID-19: a multicenter retrospective cohort study
One possible explanation is survivorship bias: the sickest patients may have died or developed other lung conditions that were classified differently. Another is diagnostic attention. People who were hospitalized for severe COVID often received extensive follow-up for their known lung damage, and any subsequent breathing problems may have been attributed to post-COVID lung scarring rather than asthma specifically. The non-hospitalized group, by contrast, may have been more likely to present months later with new wheezing and cough and receive a fresh asthma diagnosis. The discrepancy is a reminder that large database studies reflect how diagnoses are coded, not just how lungs behave.
When Post-COVID Breathing Trouble Isn’t Asthma
Not every case of breathlessness after COVID is asthma, and the overlap with other conditions is a genuine diagnostic challenge. One of the most underappreciated mimics is dysfunctional breathing, a pattern of abnormal breathing mechanics that can produce many of the same symptoms as asthma, including shortness of breath, chest tightness, and the feeling of not being able to take a deep breath. A prospective study of long COVID patients with persistent breathlessness found that nearly half had a pattern of periodic deep sighing and erratic breathing, about a fifth had hyperventilation, and a third had a mix of both. Other common complaints included faster or deeper breathing than normal, heart palpitations, and excessive yawning.8PubMed Central. Dysfunctional breathing symptoms, functional impact and quality of life in patients with long COVID-19: a prospective case series
These symptoms can easily be mistaken for asthma, and some patients end up on inhalers that do nothing for them because the underlying problem is how the brain and diaphragm coordinate breathing, not airway inflammation. The distinction matters because the treatments are completely different: dysfunctional breathing typically responds to breathing retraining and physiotherapy, not bronchodilators or steroids. If you have been given an asthma diagnosis after COVID and your inhalers are not helping, it is worth asking your doctor about this possibility.
What Post-COVID Asthma Looks Like on Testing
For the cases that are genuine asthma, the clinical picture looks remarkably similar to ordinary asthma. A study of post-COVID patients with persistent respiratory symptoms who underwent spirometry testing found that the most common symptom was cough with sputum production, present in about 83 percent of those ultimately diagnosed with asthma. Shortness of breath was next at roughly 68 percent, and wheezing appeared in about a quarter. Blood tests showed elevated eosinophils in about 72 percent, and fractional exhaled nitric oxide (FeNO), a marker of airway inflammation, was elevated in 89 percent. Most patients showed significant reversibility with bronchodilators, the hallmark diagnostic feature of asthma.9The Journal of Association of Chest Physicians. Incidence of new-onset bronchial asthma in post-COVID patients with persistent respiratory symptoms
A separate study compared the inflammatory profiles of people who developed asthma after COVID with those who had typical asthma unrelated to COVID. The results showed no significant differences in total IgE, eosinophil counts, or FeNO levels between the two groups.10PubMed Central. Inflammatory and pulmonary function characteristics of bronchial asthma induced by COVID‑19 infection In other words, once asthma develops after COVID, it behaves and looks like any other asthma. The trigger was unusual, but the disease itself is not a fundamentally different entity.
Worsening of Pre-Existing Asthma
Separate from the question of new-onset asthma is the effect of COVID on people who already have the disease. Among asthma patients who caught COVID, about a third reported that their asthma worsened afterward, compared with roughly 11 percent of asthma patients who did not have COVID. All of the patients who worsened maintained their new symptoms, had lower scores on asthma control assessments, and needed to step up their asthma medication to regain control.11PubMed Central. Worsening of asthma control after COVID-19
This is a meaningful finding for the millions of people already managing asthma. A threefold difference in worsening rates suggests that COVID can reset the baseline of disease severity. If your asthma was well-controlled before infection and has been harder to manage since, the connection is plausible and your treatment plan may need updating.
Whether Vaccination Shifts the Risk
A nationwide population-based study examined whether COVID-19 vaccination altered the risk of developing new-onset asthma. Among people who were vaccinated and then had COVID, the risk of new-onset asthma was about 18 percent lower than in matched unvaccinated controls. Fully vaccinated individuals saw a larger reduction than partially vaccinated ones. However, among people who were vaccinated but never diagnosed with COVID, vaccination alone did not reduce asthma risk.12PubMed. Increased Risk of New-Onset Asthma After COVID-19: A Nationwide Population-Based Cohort Study
This pattern suggests the vaccine’s protective effect works through reducing the severity of infection rather than through some direct effect on airway biology. Less severe COVID means less airway damage and less immune disruption, which in turn means a lower probability of triggering asthma. The study also found that older adults and people with diabetes had higher risks of post-COVID asthma regardless of vaccination status, pointing to shared vulnerability factors.
How Post-COVID Asthma Responds to Treatment
The good news for people who develop asthma after COVID is that it generally responds to standard asthma therapies. A study of patients with chronic cough following Omicron-variant COVID found that those treated with inhaled corticosteroids showed significant improvement in lung function parameters over 60 days, outperforming the group that did not receive inhaled steroids.13PubMed Central. Clinical characteristics and effects of inhaled corticosteroid in patients with post-COVID-19 chronic cough during the Omicron variant outbreak A published case report of an adult who developed asthma six months after COVID-19 infection showed that at one-year follow-up, the patient’s lung function had improved from the initial diagnosis but had not fully returned to expected values. Treatment with a combination inhaler of budesonide and formoterol provided good symptom control, and the asthma was classified as mild persistent.14Heliyon. Adult-onset asthma induced by COVID-19: A case report
Whether post-COVID asthma is permanent or can eventually resolve is still unknown. Case reports and short follow-up periods are not enough to answer that question. But the responsiveness to inhaled corticosteroids and bronchodilators means that treatment options are well-established and do not require anything exotic.
Social and Economic Factors That Complicate the Picture
The pandemic did not affect everyone equally, and neither did its respiratory aftermath. A survey of asthma patients and physicians found that minority patients were more likely to have been directly affected by COVID-related disruptions: unemployment, living in high-case communities, losing health insurance, and struggling to afford asthma medications. These patients had worse asthma control, including more emergency visits, and were less likely to have a primary care physician. A quarter of physicians reported that it was more challenging to care for Black patients with asthma during the pandemic.15PubMed Central. Asthma Disparities During the COVID-19 Pandemic: A Survey of Patients and Physicians
A study examining asthma exacerbation risk in an urban population during the pandemic found that while racial and ethnic group differences were not statistically significant after adjustment, patients with at least one unmet social need, such as housing instability, food insecurity, or lack of transportation, experienced the largest relative increase in exacerbation risk, with about a 47 percent higher odds. People on Medicaid and those in the lowest income brackets also faced elevated risk.16Scientific Reports. Effects of COVID-19 pandemic on incidence of asthma exacerbation in an urban population These findings suggest that the connection between COVID and asthma is shaped as much by access to healthcare and economic stability as by the virus itself. A person who cannot afford a follow-up appointment, fill a prescription, or take time off work to manage new symptoms is far more likely to end up with uncontrolled disease, whether the asthma is new or worsening.
The Broader Allergic Shift
One of the more intriguing findings to emerge from post-COVID research is that new-onset asthma may be part of a wider allergic tilt in the immune system after infection. The multinational cohort study that found a 2.25-fold increase in asthma risk also found a roughly 23 percent increase in allergic rhinitis and a 20 percent increase in overall allergic diseases after COVID.3Nature Communications. Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK This was not limited to one country or healthcare system; the pattern held across South Korea, Japan, and the United Kingdom.
This broader allergic tendency hints that COVID does not just injure the airways mechanically. It may reprogram parts of the immune system toward the type of inflammation associated with allergies, characterized by eosinophils, IgE, and overactive immune responses to otherwise harmless substances. If that reprogramming is real, then new-onset asthma after COVID is not an isolated respiratory event but one expression of a systemic immune shift. Researchers are still working out whether this shift fades with time, whether it can be reversed, and who is most vulnerable to it. For now, anyone who notices new seasonal allergies, sinus problems, or breathing issues in the months or years after a COVID infection has reason to take those symptoms seriously and seek evaluation rather than attributing them to coincidence.